PMID- 38492995
OWN - NLM
STAT- Publisher
LR  - 20240316
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
DP  - 2024 Feb 16
TI  - Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast 
      Carcinoma.
LID - S1526-8209(24)00046-6 [pii]
LID - 10.1016/j.clbc.2024.02.010 [doi]
AB  - INTRODUCTION: PD-L1 immunohistochemistry (IHC) is being used as a predictive 
      marker of the benefit derived from immunotherapy in several cancer types, 
      including breast cancer. However, the insight gleaned of the prognostic and 
      predictive value of PD-L1 status and its correlation with molecular 
      characteristics during breast cancer progression remains limited. METHODS: We 
      performed an PD-L1 (22C3) assay in pre-treatment primary and metastatic tumor 
      sections from 33 patients with breast carcinoma, matched for post neoadjuvant 
      chemotherapy (p-NACT). PD-L1 expression was evaluated using 3 scoring methods: 
      immune cell (IC) and tumor cell (TC) with a 1% as the cutoff value, and combined 
      positive scores (CPS) with a 1 as the cutoff value. Twenty-two samples from 11 
      patients had successful fluorescence in situ hybridization (FISH)-based molecular 
      data available for analysis. RESULTS: In the 33 pre-treatment primary tumors, 
      PD-L1 IC, TC, and CPS showed positive correlation with stromal tumor infiltrate 
      lymphocytes (sTIL), histological grade 3, and triple negative breast carcinoma 
      (TNBC). In the matched metastatic tumors, only PD-L1 IC showed a positive 
      correlation with sTIL. The primary tumors showed a higher PD-L1 expression than 
      the matched metastatic tumors by IC and CPS. Negative to positive conversion by 
      CPS was identified in the metastatic tumors from lung, pleura and liver. p-NACT 
      tumors also showed a trend of lower PD-L1 expression compared to the 
      pre-treatment tumors. Six patients had matched samples for molecular and PD-L1 
      comparison, and none of them showed consistent gene alterations or PD-L1 
      expression among the primary, p-NACT and metastatic tumors. CONCLUSION: Our study 
      showed a decrease in PD-L1 expression and disconnected molecular features during 
      breast cancer progression. Repeating PD-L1 IHC testing could be considered in 
      some specific metastatic sites if primary tumors were negative. Further studies 
      are needed to identify other predictive factors for immune checkpoint inhibitor 
      (ICI) therapy in patients with breast carcinoma.
CI  - Copyright (c) 2024 Elsevier Inc. All rights reserved.
FAU - Huang, Xiao
AU  - Huang X
AD  - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL. 
      Electronic address: xiaohuang@uabmc.edu.
FAU - Anderson, Sarah A
AU  - Anderson SA
AD  - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL.
FAU - Siegal, Gene P
AU  - Siegal GP
AD  - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL.
FAU - Wei, Shi
AU  - Wei S
AD  - Department of Pathology and Laboratory Medicine, University of Kansas Medical 
      Center, Kansas City, KS.
FAU - Liu, Shanrun
AU  - Liu S
AD  - Department of Biochemistry and Molecular Genetics, The University of Alabama at 
      Birmingham, Birmingham, AL.
FAU - Yang, Jingyun
AU  - Yang J
AD  - Department of Neurological Sciences, RUSH University, Chicago, IL.
FAU - Roisin, Puentes
AU  - Roisin P
AD  - NeoGenomics laboratories, Inc. Aliso Viejo, CA.
FAU - Pickens, J Taylor
AU  - Pickens JT
AD  - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL.
FAU - Huo, Lei
AU  - Huo L
AD  - Department of Pathology, Division of Pathology/Lab Medicine, The University of 
      Texas MD Anderson Cancer Center, Houston, TX.
FAU - Sahin, Aysegul A
AU  - Sahin AA
AD  - Department of Pathology, Division of Pathology/Lab Medicine, The University of 
      Texas MD Anderson Cancer Center, Houston, TX.
FAU - Granada, Carlos Prieto
AU  - Granada CP
AD  - Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      Medical Center, Nashville, TN.
FAU - Chen, Shuojun
AU  - Chen S
AD  - Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL.
LA  - eng
PT  - Journal Article
DEP - 20240216
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
SB  - IM
OTO - NOTNLM
OT  - Breast cancer
OT  - Fluorescence in situ hybridization
OT  - Next generation sequencing
OT  - PD-L1
OT  - Progression
COIS- Disclosure No authors have any conflicts of interest to disclose.
EDAT- 2024/03/17 00:42
MHDA- 2024/03/17 00:42
CRDT- 2024/03/16 22:57
PHST- 2023/10/04 00:00 [received]
PHST- 2024/01/18 00:00 [revised]
PHST- 2024/02/12 00:00 [accepted]
PHST- 2024/03/17 00:42 [medline]
PHST- 2024/03/17 00:42 [pubmed]
PHST- 2024/03/16 22:57 [entrez]
AID - S1526-8209(24)00046-6 [pii]
AID - 10.1016/j.clbc.2024.02.010 [doi]
PST - aheadofprint
SO  - Clin Breast Cancer. 2024 Feb 16:S1526-8209(24)00046-6. doi: 
      10.1016/j.clbc.2024.02.010.